Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines (Conference News)
Modified Vaccinia Vector Shows Promise As Cancer Vaccine
November 24th, 1997
In vitro results from using a replication deficient vaccinia virus, modified to express the human tyrosinase as a tumor associated antigen (TAA) as a cancer vaccine, are promising. I. Drexler, representing colleagues from the Institute for Molecular Virology, the Technical University of Dresden, and the Johannes Gutenberg-University, Germany, presented results at the 3rd European Conference on Gene Therapy of Cancer, held September 11-13, 1997, in Berlin, Germany, suggesting that the modified vaccinia virus Ankara (MVA) might have a successful future as a cancer immunotherapeutic. "The modified vaccinia virus Ankara, a highly attenuated vaccinia...
Source: Cancer Weekly (1997-11-24)
|
